Cargando…

Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype

HER2+ breast cancer (BC) is an aggressive subtype genetically and biologically heterogeneous. We evaluate the predictive and prognostic role of HER2 protein/gene expression levels combined with clinico-pathologic features in 154 HER2+ BCs patients who received trastuzumab-based neoadjuvant chemother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orrù, Sandra, Pascariello, Emanuele, Pes, Barbara, Rallo, Vincenzo, Barbara, Raffaele, Muntoni, Marta, Notari, Francesca, Fancello, Gianfranco, Mocci, Cristina, Muroni, Maria Rosaria, Cossu-Rocca, Paolo, Angius, Andrea, De Miglio, Maria Rosaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409859/ https://www.ncbi.nlm.nih.gov/pubmed/37553381 http://dx.doi.org/10.1038/s41598-023-40071-2

Ejemplares similares

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes
por: Orrù, Sandra, et al.
Publicado: (2022)

Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype
por: Angius, Andrea, et al.
Publicado: (2020)

Deciphering clinical significance of BCL11A isoforms and protein expression roles in triple-negative breast cancer subtype
por: Angius, Andrea, et al.
Publicado: (2022)

Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma
por: Muroni, Maria Rosaria, et al.
Publicado: (2021)

A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer
por: Angius, Andrea, et al.
Publicado: (2021)

miRNA-135b Contributes to Triple Negative Breast Cancer Molecular Heterogeneity: Different Expression Profile in Basal-like Versus non-Basal-like Phenotypes
por: Uva, Paolo, et al.
Publicado: (2018)

Portrait of Cancer Stem Cells on Colorectal Cancer: Molecular Biomarkers, Signaling Pathways and miRNAome
por: Angius, Andrea, et al.
Publicado: (2021)

Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
por: Wen, Xiaofen, et al.
Publicado: (2023)

HPV infection and triple-negative breast cancers: an Italian case-control study
por: Piana, Andrea Fausto, et al.
Publicado: (2014)

Quantitative Metabolomics to Explore the Role of Plasma Polyamines in Colorectal Cancer
por: Coradduzza, Donatella, et al.
Publicado: (2022)

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
por: Cossu-Rocca, Paolo, et al.
Publicado: (2015)

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
por: Arru, Caterina, et al.
Publicado: (2021)

A Comparative Analysis of Biomarker Selection Techniques
por: Dessì, Nicoletta, et al.
Publicado: (2013)

Landscape of transcriptome variations uncovering known and novel driver events in colorectal carcinoma
por: Pira, Giovanna, et al.
Publicado: (2020)

Integrated Analysis of miRNA and mRNA Endorses a Twenty miRNAs Signature for Colorectal Carcinoma
por: Angius, Andrea, et al.
Publicado: (2019)

MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers
por: Angius, Andrea, et al.
Publicado: (2019)

Metaproteomic Profile of the Colonic Luminal Microbiota From Patients With Colon Cancer
por: Tanca, Alessandro, et al.
Publicado: (2022)

Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis
por: Sanges, Francesca, et al.
Publicado: (2020)

Antineoplastic Properties by Proapoptotic Mechanisms Induction of Inula viscosa and Its Sesquiterpene Lactones Tomentosin and Inuviscolide
por: Migheli, Rossana, et al.
Publicado: (2022)

Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women
por: Floris, Matteo, et al.
Publicado: (2022)

Effects of memantine on mania‐like phenotypes exhibited by Drosophila Shaker mutants
por: Mocci, Ignazia, et al.
Publicado: (2023)

Clarifying the molecular mechanism of tomentosin-induced antiproliferative and proapoptotic effects in human multiple myeloma via gene expression profile and genetic interaction network analysis
por: Virdis, Patrizia, et al.
Publicado: (2021)

Tomentosin a Sesquiterpene Lactone Induces Antiproliferative and Proapoptotic Effects in Human Burkitt Lymphoma by Deregulation of Anti- and Pro-Apoptotic Genes
por: Virdis, Patrizia, et al.
Publicado: (2021)

MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North Sardinia
por: Floris, Matteo, et al.
Publicado: (2020)

Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in breast cancer: a Sardinian preliminary case-control study
por: Castiglia, Paolo, et al.
Publicado: (2019)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

Therapeutic Landscapes in Colorectal Carcinoma
por: Scanu, Antonio Mario, et al.
Publicado: (2023)

Editorial: Reviews in breast cancer
por: De Miglio, Maria Rosaria, et al.
Publicado: (2023)

Neoadjuvant PRRT for advanced pNEN: an unusual highlander
por: Zanata, Isabella, et al.
Publicado: (2021)

Non‐coding RNAs in malaria infection
por: Lodde, Valeria, et al.
Publicado: (2021)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance
por: Raman, Dayanidhi, et al.
Publicado: (2023)

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes
por: Franchina, Mariausilia, et al.
Publicado: (2023)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
por: Shen, Guoshuang, et al.
Publicado: (2021)

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Lillemoe, Tamera J., et al.
Publicado: (2021)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
por: Prat, Aleix, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tgm89tlp06a485ic3lhs0f0d3n